Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evolus Inc.

6.15
+0.01000.16%
Post-market: 6.150.00000.00%16:04 EDT
Volume:951.08K
Turnover:5.86M
Market Cap:397.82M
PE:-6.32
High:6.29
Open:6.19
Low:6.08
Close:6.14
52wk High:17.82
52wk Low:5.71
Shares:64.69M
Float Shares:50.60M
Volume Ratio:0.92
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9733
EPS(LYR):-0.8130
ROE:-18729.61%
ROA:-11.06%
PB:-21.33
PE(LYR):-7.56

Loading ...

Company Profile

Company Name:
Evolus Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
394
Office Location:
520 Newport Center Drive,Suite 1200,Newport Beach,California,United States
Zip Code:
92660
Fax:
- -
Introduction:
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Directors

Name
Position
David Moatazedi
Director, President and Chief Executive Officer
Vikram Malik
Chairman of the Board
Albert G. White, III
Independent Director
Brady Stewart
Independent Director
David Gill
Independent Director
Karah Parschauer
Independent Director

Shareholders

Name
Position
David Moatazedi
Director, President and Chief Executive Officer
Tatjana Mitchell
Chief Financial Officer
Rui Avelar
Head of Research and Development and Chief Medical Officer